Xilio Therapeutics (XLO) closed at $8.03 on October 30, 2026, up 3.3% from the previous close, on volume of 7,916 shares (30-day average 12,978).
Data as of October 30, 2026.
Market Chameleon (Mon, 26-Oct 7:21 AM ET)
Globe Newswire (Mon, 26-Oct 7:30 AM ET)
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 2-Oct 4:30 PM ET)
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
Globe Newswire (Mon, 28-Sep 7:30 AM ET)
Globe Newswire (Wed, 12-Aug 7:30 AM ET)
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Xilio Therapeutics trades on the NASDAQ stock market under the symbol XLO.
As of October 30, 2026, XLO stock price climbed to $8.03 with 7,916 million shares trading.
XLO has a beta of 0.21, meaning it tends to be less sensitive to market movements. XLO has a correlation of 0.00 to the broad based SPY ETF.
XLO has a market cap of $52.80 million. This is considered a Micro Cap stock.
Last quarter Xilio Therapeutics reported $19 million in Revenue and -$.33 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.26.
In the last 3 years, XLO traded as high as $40.51 and as low as $6.47.
The top ETF exchange traded funds that XLO belongs to (by Net Assets): VTI, VXF, IWC, DXUV, DCOR.
XLO has underperformed the market in the last year with a price return of -28.6% while the SPY ETF gained +12.3%. XLO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.6% and -6.1%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
XLO support price is $7.31 and resistance is $8.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XLO shares will trade within this expected range on the day.
